0001144204-15-022328.txt : 20150410
0001144204-15-022328.hdr.sgml : 20150410
20150410200626
ACCESSION NUMBER: 0001144204-15-022328
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150408
FILED AS OF DATE: 20150410
DATE AS OF CHANGE: 20150410
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cytosorbents Corp
CENTRAL INDEX KEY: 0001175151
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 980373793
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7 DEER PARK DRIVE, SUITE K
CITY: MONMOUTH JUNCTION
STATE: NJ
ZIP: 08852
BUSINESS PHONE: 973-329-8885
MAIL ADDRESS:
STREET 1: 7 DEER PARK DRIVE, SUITE K
CITY: MONMOUTH JUNCTION
STATE: NJ
ZIP: 08852
FORMER COMPANY:
FORMER CONFORMED NAME: MedaSorb Technologies CORP
DATE OF NAME CHANGE: 20060807
FORMER COMPANY:
FORMER CONFORMED NAME: GILDER ENTERPRISES INC
DATE OF NAME CHANGE: 20020611
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BLOCH KATHLEEN P.
CENTRAL INDEX KEY: 0001409212
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36792
FILM NUMBER: 15765593
MAIL ADDRESS:
STREET 1: 3 PERSHING COURT
CITY: NORTH BRUNSWICK
STATE: NJ
ZIP: 08902
4
1
v407031_4.xml
OWNERSHIP DOCUMENT
X0306
4
2015-04-08
0
0001175151
Cytosorbents Corp
CTSO
0001409212
BLOCH KATHLEEN P.
C/O CYTOSORBENTS CORPORATION
7 DEER PARK DRIVE, SUITE K
MONMOUTH JUNCTION
NJ
08852
0
1
0
0
Chief Financial Officer
Common Stock
2015-04-08
4
A
0
110000
0
A
110000
D
Stock Option (right to buy)
8.07
2015-04-08
4
A
0
56000
0
A
2025-04-08
Common Stock
56000
56000
D
These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan.
Such options were granted pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, 45% of which vest upon achieving 2015 budgeted revenues and not exceeding budgeted operating expenses; 30% of which vest upon achievement of multiple clinical trial objectives in calendar year 2015, as determined in the discretion of the Board of Directors; 15% of which vests upon demonstration of reasonable progress in the U.S. regulatory approval of one of CytoSorbents Corporation's products, as determined in the discretion of the Board of Directors; and 10% of which vests upon achievement of one or more new major strategic partnerships, as determined in the discretion of the Board of Directors.
/s/ Kathleen P. Bloch
2015-04-10